Profile of Margetuximab: Evidence to Date in the Targeted Treatment of Metastatic HER2-positive Breast Cancer

Human epidermal growth factor receptor 2 (HER2) positive breast cancer accounts for about 20% of all breast cancers and this subtype has been historically associated with worse prognosis. Margetuximab is a chimeric and Fc-engineered monoclonal antibody directed to HER2 that can enhance the activatio...

Descripción completa

Detalles Bibliográficos
Autores principales: Schlam, Ilana, Nunes, Raquel, Lynce, Filipa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9059982/
https://www.ncbi.nlm.nih.gov/pubmed/35509453
http://dx.doi.org/10.2147/OTT.S272197

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9059982/
https://www.ncbi.nlm.nih.gov/pubmed/35509453
http://dx.doi.org/10.2147/OTT.S272197

Ejemplares similares